source
- STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much moreBiogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tauSTAT · 3mo ago↗ source
- STAT+: Three years of declining overdose deaths begets cautious optimism and some concernsThe next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning RoundsSTAT · 3mo ago↗ source
- STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage studyBiogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.STAT · 3mo ago↗ source